Difference between revisions of "MDAI"

From DMT-Nexus Wiki
Jump to: navigation, search
(Added safety profile)
 
 
(4 intermediate revisions by one user not shown)
Line 7: Line 7:
 
* Nausea, headache, tiredness, depression, rise in blood pressure
 
* Nausea, headache, tiredness, depression, rise in blood pressure
 
|
 
|
* Mental addiction
+
* Mental addiction. WARNING: Some studies have shown that much of what is sold online as "MDAI" actually contains mephedrone or other similar drugs.
 
|
 
|
* Cardiovascular toxicity has not been tested.  As of 2013, elaborate studies on this substance have not been performed, so long term effects are still UNKNOWN!
+
* Cardiovascular toxicity has not been tested.  As of 2013, long-term studies on this substance have not been performed, so long term effects are still UNKNOWN!
 
}}
 
}}
 
== Brief overview - What is MDAI? ==
 
== Brief overview - What is MDAI? ==
  
5,6-Methylenedioxy-2-aminoindane (MDAI) is a drug developed by David E. Nichols at Purdue University in the early 1990s. It is a highly selective serotonin releasing agent (SSRA).  Like MDA and MDMA, it produces entactogenic effects.  Unlike similar drugs, it results in little to no stimulant effects.
+
5,6-Methylenedioxy-2-aminoindane (MDAI) is a drug developed by David E. Nichols at Purdue University in the early 1990s. It is a highly selective serotonin releasing agent (SSRA).  Like MDA and MDMA, it produces entactogenic effects but, unlike similar drugs, it results in little to no stimulant effects.

Latest revision as of 23:24, 19 December 2013

Safety profile Note error.png
Category:
  • Entactogen, Empathogen, SSRA
Main effects:
  • Entactogenic effects, Empathogenic effects, Euphoria
Side effects:
  • Nausea, headache, tiredness, depression, rise in blood pressure
Health risks:
  • Mental addiction. WARNING: Some studies have shown that much of what is sold online as "MDAI" actually contains mephedrone or other similar drugs.
Important safety remarks:
  • Cardiovascular toxicity has not been tested. As of 2013, long-term studies on this substance have not been performed, so long term effects are still UNKNOWN!


Brief overview - What is MDAI?

5,6-Methylenedioxy-2-aminoindane (MDAI) is a drug developed by David E. Nichols at Purdue University in the early 1990s. It is a highly selective serotonin releasing agent (SSRA). Like MDA and MDMA, it produces entactogenic effects but, unlike similar drugs, it results in little to no stimulant effects.